Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease

Cited by (532)

Items 201–300 of 532

1. Update on genetics and epigenetics in metabolic associated fatty liver disease
   Xiaopeng Zhu, Mingfeng Xia, Xin Gao · 2022 · Therapeutic Advances in Endocrinology and Metabolism
2. Genetic Contribution to Non-alcoholic Fatty Liver Disease and Prognostic Implications
   Katherine Martin, Anas Hatab, Varinder Singh Athwal, Elliot J. Jokl, Karen Piper Hanley · 2021 · Current Diabetes Reports
3. Promoting genetics in non-alcoholic fatty liver disease: Combined risk score through polymorphisms and clinical variables
   Umberto Vespasiani Gentilucci, Paolo Gallo, Chiara Dell’Unto, Mara Volpentesta, Raffaele Antonelli Incalzi, Antonio Picardi · 2018 · World Journal of Gastroenterology
4. Understanding the pathophysiological mechanisms in the pediatric non-alcoholic fatty liver disease: The role of genetics
   Pierluigi Marzuillo · 2015 · World Journal of Hepatology
5. Nutrients, Genetic Factors, and Their Interaction in Non-Alcoholic Fatty Liver Disease and Cardiovascular Disease
   Rosa Lombardi, Federica Iuculano, Giada Pallini, Silvia Rossana Fargion, Anna Ludovica Fracanzani · 2020 · International Journal of Molecular Sciences
6. The UCP 2 ‐866 G>A promoter region polymorphism is associated with nonalcoholic steatohepatitis.
   Roberta Fares, Salvatore Petta, Rosa Lombardi, Stefania Grimaudo, Paola Dongiovanni, Rosaria Maria Pipitone, Raffaela Rametta, Anna Ludovica Fracanzani, Enrico Mozzi, Antonio Craxı̀ et al. · 2014 · Liver International
7. PSD3 downregulation confers protection against fatty liver disease
   Rosellina Margherita Mancina, Kavitha Sasidharan, Anna Lindblom, Ying Wei, Ester Ciociola, Oveis Jamialahmadi, Piero Pingitore, Anne‐Christine Andréasson, Giovanni Pellegrini, Guido Baselli et al. · 2022 · Nature Metabolism
8. NADPH Oxidases Connecting Fatty Liver Disease, Insulin Resistance and Type 2 Diabetes: Current Knowledge and Therapeutic Outlook
   Alberto Nascè, Karim Gariani, François R. Jornayvaz, Ildikó Szántó · 2022 · Antioxidants
9. Integrated traditional Chinese and Western medicine in the prevention and treatment of non-alcoholic fatty liver disease: future directions and strategies
   Xin Ding, Xu He, Bulang Tang, Tian Lan · 2024 · Chinese Medicine
10. Risk Factors for the Development of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis, Including Genetics
    Huei-Wen Lim, David Bernstein · 2017 · Clinics in Liver Disease
11. Screening strategy for non-alcoholic fatty liver disease
    Saisai Zhang, Lung‐Yi Mak, Man‐Fung Yuen, Wai‐Kay Seto · 2022 · Clinical and Molecular Hepatology
12. The PNPLA3-I148M Variant Confers an Antiatherogenic Lipid Profile in Insulin-resistant Patients
    Panu K. Luukkonen, Sami U. Qadri, Tiina E. Lehtimäki, Anne Juuti, Henna E. Sammalkorpi, Anne K. Penttilä, Antti Hakkarainen, Marju Orho‐Melander, Johanna T. Arola, Hannele Yki‐Järvinen · 2020 · The Journal of Clinical Endocrinology & Metabolism
13. Combined effects of PNPLA3, TM6SF2 and HSD17B13 variants on severity of biopsy-proven non-alcoholic fatty liver disease
    Rafael Paternostro, Katharina Staufer, Stefan Traussnigg, Albert Friedrich Stättermayer, Emina Halilbasic, Omar Keritam, Elias Laurin Meyer, Judith Stift, Fritz Wrba, Bence Sipos et al. · 2021 · Hepatology International
14. Genetic Risk Factors for Metabolic Dysfunction-Associated Steatotic Liver Disease
    Yiying Pei, George Boon‐Bee Goh · 2025 · Gut and Liver
15. Influence of Ethnicity on the Accuracy of Non-Invasive Scores Predicting Non-Alcoholic Fatty Liver Disease
    Mingfeng Xia, Hannele Yki‐Järvinen, Hua Bian, Huandong Lin, Hongmei Yan, Xinxia Chang, You Zhou, Xin Gao · 2016 · PLoS ONE
16. Parental non‐alcoholic fatty liver disease increases risk of non‐alcoholic fatty liver disease in offspring
    Michelle T. Long, Ellen B. Gurary, Joseph M. Massaro, Jiantao Ma, Udo Hoffmann, Raymond T. Chung, Emelia J. Benjamin, Rohit Seth Loomba · 2018 · Liver International
17. Nonalcoholic Fatty Liver Disease and Cardiovascular Diseases: The Heart of the Matter
    Stefan Andrei Chiriac, C Stanciu, Irina Gîrleanu, Camelia Cojocariu, Catalin Victor Sfarti, Ana-Maria Sîngeap, Tudor Cuciureanu, Laura Huiban, Cristina Maria Muzica, Sebastian Zenovia et al. · 2021 · Canadian Journal of Gastroenterology and Hepatology
18. Steatohepatitis and liver fibrosis are predicted by the characteristics of very low density lipoprotein in nonalcoholic fatty liver disease
    Zhenghui Gordon Jiang, Elliot B. Tapper, Margery A. Connelly, Carolina Frade Magalhães Girardin Pimentel, Linda Feldbrügge, Mi-Sung Kim, Sarah A. Krawczyk, Nezam H. Afdhal, Simon Christopher Robson, Mark A. Herman et al. · 2016 · Liver International
19. Protein phosphatase 1 regulatory subunit 3B gene variation protects against hepatic fat accumulation and fibrosis in individuals at high risk of nonalcoholic fatty liver disease
    Paola Dongiovanni, Marica Meroni, Rosellina Margherita Mancina, Guido Baselli, Raffaela Rametta, Serena Pelusi, Ville Männistö, Anna Ludovica Fracanzani, Sara Badiali, Luca Miele et al. · 2018 · Hepatology Communications
20. Genetic determinants of hepatic steatosis and serum cytokeratin‐18 fragment levels in Taiwanese children
    Yu‐Cheng Lin, Pi‐Feng Chang, Mei‐Hwei Chang, Yen‐Hsuan Ni · 2018 · Liver International
21. A Systematic Review of NAFLD-Associated Extrahepatic Disorders in Youths
    Lucia Pacifico, Francesco Massimo Perla, Mario Roggini, Gian Marco Andreoli, Miriam D’Avanzo, Claudio Chiesa · 2019 · Journal of Clinical Medicine
22. Novel Insights into the Genetic Landscape of Nonalcoholic Fatty Liver Disease
    Alice Emma Taliento, Marcello Dallio, Alessandro Federico, Daniele Prati, Luca V. C. Valenti · 2019 · International Journal of Environmental Research and Public Health
23. Effect of common genetic variants on the risk of cirrhosis in non‐alcoholic fatty liver disease during 20 years of follow‐up
    Magnus Holmer, Mattias Ekstedt, Patrik Nasr, Robin Zenlander, Axel Wester, Federica Tavaglione, Stefano Romeo, Stergios Kechagias, Per I Stal, Hannes Hagström · 2022 · Liver International
24. Concise review of lipidomics in nonalcoholic fatty liver disease
    Sarah Béland‐Bonenfant, Alexia Rouland, Jean‐Michel Petit, Bruno L Vergès · 2023 · Diabetes & Metabolism
25. Precision medicine and nucleotide-based therapeutics to treat steatotic liver disease
    Andrea Marco Caddeo, Stefano Romeo · 2024 · Clinical and Molecular Hepatology
26. Pathophysiology of Nonalcoholic Fatty Liver Disease: Lifestyle-Gut-Gene Interaction
    Arianna Mazzotti, Maria Turchese Caletti, Anna Simona Sasdelli, Lucia Brodosi, Giulio Marchesini · 2016 · Digestive Diseases
27. Non-alcoholic fatty liver disease is a strong predictor of coronary artery calcification in metabolically healthy subjects: A cross-sectional, population-based study in middle-aged subjects
    Anders Gummesson, Ulf Strömberg, Caroline Bergstro Schmidt, Joel Kullberg, Oskar Angerås, Stefan C. Lindgren, Ola Hjelmgren, Kjell Torén, Annika Rosengren, Björn Fagerberg et al. · 2018 · PLoS ONE
28. Meta-analysis of the association between MBOAT7 rs641738, TM6SF2 rs58542926 and nonalcoholic fatty liver disease susceptibility
    Yan Xia, Chunxia Huang, Guangyi Li, Kai-Hua Chen, Han Li, Liang Tang, Huaiqing Luo, Meihua Bao · 2019 · Clinics and Research in Hepatology and Gastroenterology
29. Biosynthesis and Metabolism of ApoB-Containing Lipoproteins
    Jan Borén, Marja‐Riitta Taskinen, Chris J. Packard · 2024 · Annual Review of Nutrition
30. TM6SF2 E167K Variant, a Novel Genetic Susceptibility Variant, Contributing to Nonalcoholic Fatty Liver Disease
    Lizhen Chen, Harry Hua‐Xiang Xia, Yongning Xin, Zhonghua Lin, Shiying Xuan · 2015 · Journal of Clinical and Translational Hepatology
31. TM6SF2 rs58542926 is related to hepatic steatosis, fibrosis and serum lipids both in adults and children: A meta-analysis
    Xueying Li, Zheng Liu, Li Li, Haijun Wang, Hui Wang · 2022 · Frontiers in Endocrinology
32. Advances in the genetics of nonalcoholic fatty liver disease
    Veeral H. Ajmera, Rohit Seth Loomba · 2023 · Current Opinion in Gastroenterology
33. TM6SF2: A novel target for plasma lipid regulation
    Tingting Li, Tao‐Hua Li, Juan Peng, Bei He, Lu-Shan Liu, Dangheng Wei, Zhi‐Sheng Jiang, Xi‐Long Zheng, Zhi‐Han Tang · 2017 · Atherosclerosis
34. Hepatocellular carcinoma in the post-hepatitis C virus era: Should we change the paradigm?
    Hadar Meringer, Oren Shibolet, Liat Deutsch · 2019 · World Journal of Gastroenterology
35. The Pathogenesis of HCC Driven by NASH and the Preventive and Therapeutic Effects of Natural Products
    Gaoxuan Shao, Ying Liu, Lu Lu, Guangtao Zhang, Wenjun Zhou, Tao Wu, Lei Wang, Hanchen Xu, Guang Ji · 2022 · Frontiers in Pharmacology
36. The effect of the TM6SF2 E167K variant on liver steatosis and fibrosis in patients with chronic hepatitis C: a meta-analysis
    Zhengtao Liu, Shuping Que, Lin Zhou, Shusen Zheng, Stefano Romeo, Adil Mardinoğlu, Luca V. C. Valenti · 2017 · Scientific Reports
37. Fatty Liver Disease
    DINA G. TINIAKOS, Quentin Mark Anstee, Alastair D. Burt · 2017 · Elsevier eBooks
38. PNPLA3 and TM6SF2 polymorphisms in Brazilian patients with nonalcoholic fatty liver disease
    Quelson Coelho Lisboa, Mateus Jorge Nardelli, Patrícia de Araújo Pereira, Débora Marques de Miranda, Stephanie Nunes Ribeiro, Raíssa Soares Neves da Costa, Camila Azevedo Versiani, Paula Vieira Teixeira Vidigal, Teresa Cristina Abreu Ferrari, Cláudia Alves Couto · 2020 · World Journal of Hepatology
39. Heterogeneity of non-alcoholic fatty liver disease (NAFLD): Implication for cardiovascular risk stratification
    Francesco Baratta, Laura D’Erasmo, Simone Bini, Daniele Pastori, Francesco Angelico, Maria Del Ben, Marcello Arca, Alessia Di Costanzo · 2022 · Atherosclerosis
40. Lipid and Lipoprotein Metabolism in Liver Disease
    Ashwini Arvind, Stephanie A. Osganian, David E. Cohen, Kathleen E. Corey · 2015 · MDText.com, Inc. eBooks
41. Genetic Risk Factors and Disease Modifiers of Nonalcoholic Steatohepatitis
    Julia Kozlitina · 2020 · Gastroenterology Clinics of North America
42. Gut microbiota in MAFLD: therapeutic and diagnostic implications
    Waleed Alghamdi, Mahmoud Hisham Mosli, Saleh A. Alqahtani · 2024 · Therapeutic Advances in Endocrinology and Metabolism
43. Reduction of Caloric Intake Might Override the Prosteatotic Effects of the PNPLA3 p.I148M and TM6SF2 p.E167K Variants in Patients with Fatty Liver: Ultrasound-Based Prospective Study
    Marcin Jan Krawczyk, Ewa Stachowska, Piotr Milkiewicz, Frank Lammert, Małgorzata Milkiewicz · 2016 · Digestion
44. Nutrigenomics and Nutrigenetics in Metabolic- (Dysfunction) Associated Fatty Liver Disease: Novel Insights and Future Perspectives
    Marcello Dallio, Mario Romeo, Antonietta Gerarda Gravina, Mario Masarone, Tiziana Larussa, Ludovico Abenavoli, Marcello Persico, C. Loguercio, Alessandro Federico · 2021 · Nutrients
45. The Emerging Factors and Treatment Options for NAFLD-Related Hepatocellular Carcinoma
    Chunye Zhang, Ming Jun Yang · 2021 · Cancers
46. Depletion of TM6SF2 disturbs membrane lipid composition and dynamics in HuH7 hepatoma cells
    Ruhanen, Hanna, Nidhina Haridas, P.A., Eskelinen, Eeva-Liisa, Eriksson, Ove, Olkkonen, Vesa M., Käkelä, Reijo · 2017 · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids
47. Unraveling Metabolic Dysfunction-Associated Steatotic Liver Disease Through the Use of Omics Technologies
    Maria V. Bourganou, Maria Eleni Chondrogianni, Ioannis Kyrou, Christina‐Maria Flessa, Antonios Chatzigeorgiou, Evangelos K. Oikonomou, Vaia Lambadiari, Harpal Singh Randeva, Eva N. Kassi · 2025 · International Journal of Molecular Sciences
48. Role of Myeloid-Epithelial-Reproductive Tyrosine Kinase and Macrophage Polarization in the Progression of Atherosclerotic Lesions Associated With Nonalcoholic Fatty Liver Disease
    Mirella Pastore, Stefania Grimaudo, Rosaria Maria Pipitone, Giulia Lori, Chiara Raggi, Salvatore Petta, Fabio Marra · 2019 · Frontiers in Pharmacology
49. The KLB rs17618244 gene variant is associated with fibrosing MAFLD by promoting hepatic stellate cell activation
    Nadia Panera, Marica Meroni, Miriam Longo, Annalisa Crudele, Luca V. C. Valenti, Emanuele Bellacchio, Luca Miele, Valentina Doria, Erika Paolini, Marco Maggioni et al. · 2021 · EBioMedicine
50. Collagen Formation Assessed by N‐Terminal Propeptide of Type 3 Procollagen Is a Heritable Trait and Is Associated With Liver Fibrosis Assessed by Magnetic Resonance Elastography
    Cyrielle Caussy, Meera Bhargava, Ida Falk Villesen, Natasja Stæhr Gudmann, Diana Julie Leeming, M.A. Karsdal, Claire Faulkner, Denny Bao, Amy Liu, Min‐Tzu Lo et al. · 2019 · Hepatology
51. Systematic review of genetic association studies involving histologically confirmed non-alcoholic fatty liver disease
    Kayleigh L. Wood, Michael H. Miller, John Francis Dillon · 2015 · BMJ Open Gastroenterology
52. Genetics in non-alcoholic fatty liver disease: The role of risk alleles through the lens of immune response
    Silvia C. Sookoian, Carlos Jose Pirola · 2022 · Clinical and Molecular Hepatology
53. NAFLD Fibrosis Progression and Type 2 Diabetes: The Hepatic–Metabolic Interplay
    Simona Cernea · 2024 · Life
54. Metabolic Dysfunction-Associated Steatotic Liver Disease: Pathogenetic Links to Cardiovascular Risk
    Vlad Ionescu, Gina Gheorghe, Nicolae Bacalbaşa, Camelia Cristina Diaconu · 2025 · Biomolecules
55. Patatin‐like phospholipase domain containing 3 variants differentially impact metabolic traits in individuals at high risk for cardiovascular events
    Sabrina Rüschenbaum, Katharina Maria Schwarzkopf, Mireen Friedrich‐Rust, Florian Hartmut Seeger, Fabian Schoelzel, Yolanda Martinez, Stefan Zeuzem, Jörg Bojunga, Christian Markus Lange · 2018 · Hepatology Communications
56. Interaction of TM6SF2 E167K and PNPLA3 I148M variants in NAFLD in northeast China
    Min Xu, Yiling Li, Shuang Zhang, Xinyi Wang, Jianhua Shen, Shuwen Zhang · 2019 · Annals of Hepatology
57. Genetic Susceptibility to Chronic Liver Disease in Individuals from Pakistan
    Asad Mehmood Raja, Ester Ciociola, Imran Ahmad, Faisal Saud Dar, Syed Naqvi, Muhammad Moaeen-ud-Din, Ghazala Kaukab Raja, Stefano Romeo, Rosellina Margherita Mancina · 2020 · International Journal of Molecular Sciences
58. Gene-Environmental Interactions as Metabolic Drivers of Nonalcoholic Steatohepatitis
    Somaya A. M. Albhaisi, Arun Jayant Sanyal · 2021 · Frontiers in Endocrinology
59. The role of PCSK9 in NAFLD/NASH and therapeutic implications of PCSK9 inhibition
    Amir Abbas Momtazi‐Borojeni, Maciej Banach, Massimiliano Ruscica, Amirhossein Sahebkar · 2022 · Expert Review of Clinical Pharmacology
60. Genetic Polymorphisms and Diversity in Nonalcoholic Fatty Liver Disease (NAFLD): A Mini Review
    Siti Aishah Sulaiman, Vicneswarry Dorairaj, Muhammad Nafiz Haidi Adrus · 2022 · Biomedicines
61. Fatty Liver Disease, Metabolism and Alcohol Interplay: A Comprehensive Review
    Aitor Odriozola, Álvaro Santos‐Laso, María Del Barrio, Joaquín Cabezas, Paula Iruzubieta, M. Arias, Coral Rivas, Juan Carlos Rodríguez Duque, Ángela Antón, Emilio Fábrega et al. · 2023 · International Journal of Molecular Sciences
62. The common PNPLA 3 variant p.I148M is associated with liver fat contents as quantified by controlled attenuation parameter ( CAP )
    Anita Arslanow, Caroline S. Stokes, Susanne Nicole Weber, F Grünhage, Frank Lammert, Marcin Jan Krawczyk · 2015 · Liver International
63. Fatty liver without a large “belly”: Magnified review of non-alcoholic fatty liver disease in non-obese patients
    Mohamad Yousef, Alhareth Al Juboori, Abdulmajeed A. Albarrak, Jamal A. Ibdah, Veysel Tahan · 2017 · World Journal of Gastrointestinal Pathophysiology
64. Donor PNPLA3 and TM6SF2 Variant Alleles Confer Additive Risks for Graft Steatosis After Liver Transplantation
    Irena Míková, Magdaléna Neřoldová, Jaroslav Alois Hubacek, Dana Dlouhá, Milan Jirsa, Eva Honsová, Eva Sticová, Věra Lánská, Julius Špičák, Pavel Trunečka · 2019 · Transplantation
65. The lipidome in nonalcoholic fatty liver disease: actionable targets
    Carlos Jose Pirola, Silvia C. Sookoian · 2021 · Journal of Lipid Research
66. Genetics, Immunity and Nutrition Boost the Switching from NASH to HCC
    Paola Dongiovanni, Marica Meroni, Miriam Longo, Silvia Rossana Fargion, Anna Ludovica Fracanzani · 2021 · Biomedicines
67. Impact of PNPLA3 and TM6SF2 polymorphisms on the prognosis of patients with MASLD and type 2 diabetes mellitus
    Natália Lavrado, Gil Fernando Salles, Claudia R.L. Cardoso, Paulo Henrique Condeixa de França, Maria Fernanda Di Guimarães Gonçalves Melo, Nathalie Carvalho Leite, Cristiane Alves Villela‐Nogueira · 2024 · Liver International
68. Large-scale identification of undiagnosed hepatic steatosis using natural language processing
    Carolin Victoria Schneider, Tang Li, David Zhang, Anya I. Mezina, Puru Rattan, Helen Ye Rim Huang, Kate Townsend Creasy, Eleonora Scorletti, Inuk Zandvakili, Marijana Vujković et al. · 2023 · EClinicalMedicine
69. Dysfunctional VLDL metabolism in MASLD
    Urko M. Marigorta, Óscar Millet, Shelly Chi-Loo Lu, José María Mato · 2024 · npj Metabolic Health and Disease
70. Human genetics of steatotic liver disease: insights into insulin resistance and lipid metabolism
    Rosellina Margherita Mancina, Luca V. C. Valenti, Stefano Romeo · 2025 · Nature Metabolism
71. Genetics and epigenetics purpose in nonalcoholic fatty liver disease
    Alan Eduardo Botello-Manilla, Norberto Carlos Chávez-Tapia, Misael Uribe, Natalia Nuño‐Lámbarri · 2020 · Expert Review of Gastroenterology & Hepatology
72. EHBP1 suppresses liver fibrosis in metabolic dysfunction-associated steatohepatitis
    Fanglin Ma, Miriam Longo, Marica Meroni, Dipankar Bhattacharya, Erika Paolini, Shama Mughal, Syed Hussain, Sumit Kumar Anand, Neha Gupta, Yiwei Zhu et al. · 2025 · Cell Metabolism
73. New insights into genetic predisposition and novel therapeutic targets for nonalcoholic fatty liver disease
    Mary Barbara, Andrea Leah Scott, Naim Alkhouri · 2018 · HepatoBiliary Surgery and Nutrition
74. Genetics of Non-Alcoholic Fatty Liver and Cardiovascular Disease: Implications for Therapy?
    Karthik H. Chandrasekharan, William Alazawi · 2020 · Frontiers in Pharmacology
75. Nonalcoholic fatty liver disease: one entity, multiple impacts on liver health
    Carmen Georgeta Fierbinteanu-Braticevici, Crina Julieta Sinescu, Alexandru Constantin Moldoveanu, Ana Petrişor, Sorina Diaconu, Dragoş Crețoiu, Bogdan Braticevici · 2016 · Cell Biology and Toxicology
76. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: new trends and role of ultrasonography
    Toshifumi Tada, Takashi Nishimura, Masahiro Yoshida, Hiroko Iijima · 2020 · Journal of Medical Ultrasonics
77. The role of PNPLA3 and TM6SF2 polymorphisms on liver fibrosis and metabolic abnormalities in Brazilian patients with chronic hepatitis C
    Arthur Ivan Nobre Oliveira, Fernanda de Mello Malta, Patrícia Momoyo Zitelli, Ana Paula Moreira Salles, Michele Soares Gomes‐Gouvêa, Ana Catharina de Seixas Santos Nastri, João Renato Rebello Pinho, Flair José Carrilho, Claudia Pinto Marques Souza de Oliveira, Maria Cássia Mendes-Corrêa et al. · 2021 · BMC Gastroenterology
78. Inborn and acquired risk factors for severe liver disease in Europeans with type 2 diabetes from the UK Biobank
    Federica Tavaglione, Antonio De Vincentis, Oveis Jamialahmadi, Roberta Pujia, Rocco Spagnuolo, Antonio Picardi, Susanna Morano, Luca V. C. Valenti, Stefano Romeo, Umberto Vespasiani Gentilucci · 2021 · JHEP Reports
79. The rs599839 A>G Variant Disentangles Cardiovascular Risk and Hepatocellular Carcinoma in NAFLD Patients
    Marica Meroni, Miriam Longo, Erika Paolini, Anna Alisi, Luca Miele, Emilia Rita De Caro, Giuseppina Pisano, Marco Maggioni, Giorgio Soardo, Luca V. C. Valenti et al. · 2021 · Cancers
80. Innate Immune System in the Pathogenesis of Non-Alcoholic Fatty Liver Disease
    Dae Won Ma, Joohun Ha, Kyung‐Sik Yoon, Insug Kang, Tae Gyu Choi, Sung Soo Kim · 2023 · Nutrients
81. Metabolic Dysfunction-Associated Steatotic Liver Disease: A Silent Driver of Cardiovascular Risk and a New Target for Intervention
    Giovanna Gallo, Gabriele Nalli, Francesco Baratta, Giovambattista Desideri, Carmine Savoia · 2025 · International Journal of Molecular Sciences
82. Associations between metabolic hyperferritinaemia, fibrosis‐promoting alleles and clinical outcomes in steatotic liver disease
    Deepika Suresh, Ashley Li, Matthew J. Miller, Karn Wijarnpreecha, Vincent Lingzhi Chen · 2023 · Liver International
83. Meta-analysis of the influence of TM6SF2 E167K variant on Plasma Concentration of Aminotransferases across different Populations and Diverse Liver Phenotypes
    Silvia C. Sookoian, Carlos Jose Pirola · 2016 · Scientific Reports
84. Immunological dynamics in MASH: from landscape analysis to therapeutic intervention
    Lawan Rabiu, Pengchao Zhang, L. O. Afolabi, M. Saliu, Salisu M. Dabai, R. B. Suleiman, Khalid I Gidado, M. A. Ige, Abdulrahman Ibrahim, Gui-Zhong Zhang et al. · 2024 · Journal of gastroenterology
85. Liver fibrogenesis: un update on established and emerging basic concepts
    Erica Novo, Claudia Bocca, Beatrice Foglia, Francesca Protopapa, Marina Maggiora, Maurizio Parola, Stefania Cannito · 2020 · Archives of Biochemistry and Biophysics
86. Loss of Hepatic Leucine-Rich Repeat-Containing G-Protein Coupled Receptors 4 and 5 Promotes Nonalcoholic Fatty Liver Disease
    Saponara, Enrica, Penno, Carlos, Orsini, Vanessa, Wang, Zhong-Yi, Fischer, Audrey, Aebi, Alexandra, Matadamas-Guzman, Meztli L., Brun, Virginie, Fischer, Benoit, Brousseau, Margaret et al. · 2023 · The American Journal of Pathology
87. Metabolic dysfunction-associated steatotic liver disease: A pathophysiology and clinical framework to face the present and the future
    Salvatore Corrao, Luigi Calvo, Walter Granà, Salvatore Scibetta, Luigi Mirarchi, Simona Amodeo, Fabio Falcone, Christiano Argano · 2024 · Nutrition Metabolism and Cardiovascular Diseases
88. Transmembrane-6 superfamily member 2 (TM6SF2) E167K variant increases susceptibility to hepatic steatosis in obese children
    Rosellina Margherita Mancina, Federica Sentinelli, Michela Incani, Laura Bertoccini, Cristina Russo, Stefano Romeo, Marco Giorgio Baroni · 2015 · Digestive and Liver Disease
89. Combining Genetic Variants to Improve Risk Prediction for NAFLD and Its Progression to Cirrhosis: A Proof of Concept Study
    Umberto Vespasiani Gentilucci, Chiara Dell’Unto, Antonio De Vincentis, Andrea Baiocchini, Marco Delle Monache, Roberto Cecere, Adriano Maria Pellicelli, Valerio Giannelli, Simone Carotti, Giovanni Galati et al. · 2018 · Canadian Journal of Gastroenterology and Hepatology
90. Effects of Moderate Alcohol Consumption in Non-Alcoholic Fatty Liver Disease
    Peter Lemmer, Paul Peter Manka, Jan Best, Alişan Kahraman, Julia Kälsch, Ramiro Vilchez‐Vargas, Alexander Link, Hsin Chiang, Guido Gerken, Ali E. Canbay et al. · 2022 · Journal of Clinical Medicine
91. African genetic ancestry is associated with lower frequency of PNPLA3 G allele in non-alcoholic fatty liver in an admixed population.
    L. Cavalcante, Jun Porto, D. Mazo, A. Longatto-Filho, J. Stefano, A. Lyra, F. Carrilho, R. Reis, V. Alves, A. Sanyal et al. · 2022 · Annals of Hepatology
92. Metabolic syndrome but not genetic polymorphisms known to induce NAFLD predicts increased total mortality in subjects with NAFLD (OPERA study)
    Aki Juhani Käräjämäki, Janne Hukkanen, Heikki Kauma, Y. Antero Kesäniemi, Olavi H. Ukkola · 2019 · Scandinavian Journal of Clinical and Laboratory Investigation
93. Genetic risk factors associated with NAFLD
    Dong Yun Kim, Jun Yong Park · 2020 · Hepatoma Research
94. Occult hepatitis B virus infection predicts non‐alcoholic steatohepatitis in severely obese individuals from Italy
    Giovanni Raimondo, Carlo Saitta, Daniele Lombardo, Pablo José Giraudi, Natalia Rosso, Antonio Ieni, Salvatore Lazzara, Silvia Palmisano, Deborah Bonazza, Angela Alibrandi et al. · 2020 · Liver International
95. Therapeutic Attributes of Endocannabinoid System against Neuro-Inflammatory Autoimmune Disorders
    Ishtiaq Ahmed, Saif ur Rehman, Shiva Shahmohamadnejad, Muhammad Anjum Zia, Muhammad Mubeen Ahmad, Muhammad Muzammal Saeed, Zain Akram, Hafiz M.N. Iqbal, Qingyou Liu · 2021 · Molecules
96. Epidemiology and disease burden of non-alcoholic steatohepatitis in greater China: a systematic review
    Huimin Zou, Ying Ge, Qing Lei, Carolina Oi Lam Ung, Zhen Ruan, Yunfeng Lai, Dongning Yao, Hao Hu · 2022 · Hepatology International
97. Influence of Type 2 Diabetes in the Association of PNPLA3 rs738409 and TM6SF2 rs58542926 Polymorphisms in NASH Advanced Liver Fibrosis
    Pablo Gabriel-Medina, Roser Ferrer, Francisco Rodríguez‐Frias, Andreea Ciudin, Salvador Augustín, Jesús Rivera‐Esteban, Juan Manuel Pericàs, David M. Selva · 2022 · Biomedicines
98. Nonalcoholic Fatty Liver Disease in Children.
    Katherine F. Sweeny, Christine K Lee · 2021 · PubMed Central
99. Noninvasive Testing for NASH and NASH with Advanced Fibrosis: Are We There Yet?
    Ahilan Arulanandan, Rohit Seth Loomba · 2015 · Current Hepatology Reports
100. Reply to: HCC and liver disease risk in homozygous PNPLA3 p.I148M carriers approach monogenic inheritance
     Quentin Mark Anstee, Yang‐Lin Liu, Christopher Paul Day, Helen Louise Reeves · 2015 · Journal of Hepatology